Please login to the form below

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Also coming through the pipeline is Biogen’s Tecfidera follow-up diroximel fumarate (BIIB098), Novartis’ new antibody ofatumumab, and Celgene’s S1P receptor modulator ozanimod that is due for regulatory decision

Latest news

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Fedratinib was one of the late-stage development programmes highlighted by BMS when the merger was announced in January, although others – such as multiple sclerosis drug ozanimod and CAR-T cancer
Triplet approvals for myeloma boost Celgene in Q2

Also nearing the market are fedratinib for myelofibrosis which could be approved in September, luspatercept for myelodysplastic syndromes – with an FDA decision due next April – and ozanimod for multiple sclerosis, which
Post-merger Celgene to lead pharma growth

Celgene also has five potential blockbusters in its late-stage pipeline, including MS treatment ozanimod and myelodysplastic syndromes/beta thalassemia candidate luspatercept, which have both recently been filed.
Celgene files luspatercept ahead of key merger vote

The drug is one of five late-stage pipeline drugs from Celgene tipped for blockbuster status (the first being the just-re-filed ozanimod) and the filing comes just days ahead
FDA approves Novartis' next-gen MS drug Mayzent

The approval comes just one day after Celgene its MS treatment, ozanimod, which is likely to be a close rival to Novartis' drug once approved.

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

Pharma deals in July 2015

Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.